Hormonal decline (andropause / menopause)
Structured hormone assessment for the age-related decline in reproductive hormones, with other explanations excluded before symptoms are attributed to hormonal decline alone.
What it is
Andropause in men and menopause (and the preceding perimenopause transition) in women describe the age-related decline in reproductive hormone production, primarily testosterone in men and estrogen/progesterone in women, affecting energy, mood, body composition, sexual function, bone density, and metabolic health. The transition is gradual and highly individual in timing and severity, and overlapping causes such as thyroid dysfunction, depression, and sleep disorders are excluded before symptoms are attributed to hormonal decline alone.
Common symptoms & concerns
- Reduced energy, motivation, or libido
- Hot flashes, night sweats, or noticeable mood changes
- Reduced muscle mass, exercise recovery, or sexual function
- Sleep disruption affecting daytime function
- Menstrual-cycle irregularity (perimenopause) or measurable bone density and metabolic changes in more advanced presentations
Assessment approach
Assessment begins with hormone panels and a review of overlapping causes, so hormone therapy is only initiated following diagnostic confirmation of deficiency on laboratory testing, not on symptom report alone.
In-scope care
In-scope care includes hormone panels and, where clinically indicated, hormone optimization/replacement therapy, alongside Ayurvedic lifestyle support, constitutional homeopathy, and mind-body practices for the sleep and mood component. Cardiovascular, bone, and oncological risks and benefits are reviewed individually before treatment begins.
Treatments used
Related questions
Timing varies widely between individuals. Menopause in women commonly occurs around the late 40s to early 50s, often preceded by a perimenopause transition of several years; andropause-related decline in men is more gradual and less clearly age-bound.
Not automatically. Hormone therapy is considered only after laboratory testing confirms a genuine deficiency and other explanations have been excluded; the decision is individualized.
Risks and benefits vary by individual health history, including cardiovascular, bone, and oncological considerations, and are reviewed case by case before treatment begins, following current clinical guidelines.